Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Scleraxis (SCX) is a basic helix-loop-helix (bHLH) transcription factor critical for tendon and ligament development, maintenance, and repair[1][4][3]. It is expressed early in embryonic tendon progenitor cells and persists through tenocyte maturation[1][3]. SCX regulates the transcription of numerous extracellular matrix component genes necessary for tendon structure and function, and its loss results in severe hypoplasia or absence of force-transmitting tendons in animal models[1][4]. SCX function operates downstream of signaling pathways such as FGF and TGFβ during musculoskeletal development[3][4]. Although primarily a developmental biology marker and regulator, SCX's dysregulation has implications in congenital musculoskeletal disorders and tissue regeneration models, but there are currently no approved therapeutic drugs directly targeting SCX[1][4][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Scleraxis basic helix-loop-helix transcription factor (SCX).